Trial Profile
Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Therapeutic Use
- Acronyms BELIEVE; BELIEVE 1
- Sponsors Zynerba Pharmaceuticals
- 07 Sep 2021 According to a Zynerba Pharmaceuticals media release, the company announces publication of results in the Journal of the American Medical Association (JAMA) Network Open under the article titled "Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies: A nonrandomized controlled trial"
- 07 Sep 2021 Results published in the Zynerba Pharmaceuticals Media Release
- 11 Jun 2021 According to a Zynerba Pharmaceuticals media release, data poster presented at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies.